© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90627 refers to the tick-borne encephalitis virus vaccine, which is an inactivated vaccine specifically designed for intramuscular administration. This vaccine is crucial for providing protection against tick-borne encephalitis (TBE), a viral infection that can have severe consequences, including neurological complications such as muscle weakness, cognitive decline, and in some cases, permanent paralysis or death. Unlike immune globulins that offer temporary, passive immunity, this vaccine works by stimulating the recipient's immune system to develop active, long-lasting immunity. It does this by introducing altered forms of the TBE virus, prompting the immune system to produce antibodies that can effectively combat the virus upon future exposure. The TICOVAC™ vaccine, which received approval in the U.S. in 2021, is effective for both children and adults who are traveling to or living in areas where TBE is prevalent. While the virus is not endemic in the United States, it poses a significant risk in various regions of Europe and Asia. For accurate reporting, it is important to note that code 90627 is designated for the 0.5 mL dosage of the vaccine, while a separate code, 90626, is used for the 0.25 mL dosage. Additionally, the administration of the vaccine via intramuscular injection should be reported separately, with the injection typically occurring in the arm for adults and in the thigh for children.
© Copyright 2025 Coding Ahead. All rights reserved.
The tick-borne encephalitis virus vaccine (CPT® Code 90627) is indicated for individuals who are at risk of exposure to the tick-borne encephalitis virus. This includes:
The administration of the tick-borne encephalitis virus vaccine involves several key procedural steps:
Following the administration of the tick-borne encephalitis virus vaccine, patients may experience mild side effects such as soreness at the injection site, low-grade fever, or fatigue. These symptoms typically resolve within a few days. It is important for patients to be informed about these potential reactions and to seek medical attention if they experience severe or persistent symptoms. Additionally, patients should be advised on the importance of completing the vaccination series, if required, to ensure optimal protection against tick-borne encephalitis.
| Short Descr | TIC-BRN ENCEPH VAC 0.5ML IM | Medium Descr | TICK-BORNE ENCEPH VACC INACTIVATED 0.5ML IM USE | Long Descr | Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use | Status Code | Non-Covered Service | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Non-Covered Service, not paid under OPPS | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2023-01-01 | Note | First appearance of the removal of the FDA approval icon in codebook. |
| 2022-07-01 | Changed | FDA approval granted. |
| 2022-01-01 | Added | First appearance in codebook. |
| 2021-07-01 | Added | Code added. Effective upon receiving emergency Use Authorization or approval from the FDA. |
Get instant expert-level medical coding assistance.